A UK company that makes medicines from cannabis has raised nearly $90m on New York’s Nasdaq stock exchange to develop a treatment for childhood epilepsy.
GW Pharmaceuticals already sells a marijuana-based drug across Europe as a treatment for multiple sclerosis and believes the plant’s properties have potential for use in a wider range of pharmaceutical products.
